Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …

Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation
(AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated
despite a lack of contraindications to vitamin K antagonists (VKAs) like warfarin. These …

Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background—Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …